Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Lintlafatso tse Bohlokoa ho Botenya ba Mafu bakeng sa Atopic Dermatitis

ngotsoeng ke mohlophisi

Libekeng tse 16, karolo ea 70 lekholong ea bakuli ba nang le "atopic dermatitis" e leka-lekaneng ho isa ho e matla (AD) ba fumanang lebrikizumab hammoho le "standard-of-care topical corticosteroids" (TCS) ba fihletse bonyane ntlafatso ea karolo ea 75 lekholong ho boima ba lefu ka kakaretso (EASI-75 *) teko ea ADhere, Eli Lilly and Company (NYSE: LLY) e phatlalalitse kajeno Kopanong ea 4 ea Selemo le Selemo ea Revolutionizing Atopic Dermatitis (RAD). Lebrikizumab, IL-13 inhibitor ea lipatlisiso, le eona e bontšitse ntlafatso ea ho hlohlona, ​​tšitiso ea boroko, le boleng ba bophelo ha e kopantsoe le TCS, ha e bapisoa le placebo hammoho le TCS.

"Lintlha tsa kajeno tsa ADhere, hammoho le liphetho tsa lithuto tsa bo-Advocate monotherapy, li bonts'a monyetla oa hore lebrikizumab e fokotse moroalo oa mafu le ho fana ka phomolo ho batho ba nang le atopic dermatitis e sa laoleheng ha e sebelisoa e le mong kapa e kopantsoe le lihlooho," ho boletse Eric Simpson, MD, MCR. Moprofesa oa Dermatology le Motsamaisi oa Lipatlisiso tsa Clinical Univesithing ea Oregon Health & Science e Portland, le mofuputsi ea ka sehloohong oa ADhere. "Lebrikizumab e shebile ka ho khetheha tsela ea IL-13, e bapalang karolo ea mantlha lefung lena le sa foleng la ho ruruha. Liphetho tsena li matlafatsa kutloisiso ea rona ea lebrikizumab ho atopic dermatitis le ho re thusa ho e theha e le khetho e ncha ea kalafo.

Lebrikizumab ke buka, monoclonal antibody (mAb) e tlamang protheine ea interleukin 13 (IL-13) e nang le kamano e phahameng ho thibela ka ho khetheha ho thehoa ha IL-13Rα1 / IL-4Rα (Mofuta oa 2 receptor) e thibelang pontšo e tlaase ka IL. -13 pathway.1-5 IL-13 e phetha karolo ea mantlha ho ruruha ha Mofuta oa 2 ka AD.6,7 Ka AD, IL-13 e fana ka matšoao le matšoao a kenyeletsang ho se sebetse ha mokoallo oa letlalo, ho hlohlona, ​​tšoaetso le libaka tse thata, tse teteaneng tsa letlalo. .8

Har'a bakuli ba nkang lebrikizumab hammoho le TCS, karolo ea 41 lekholong e fihletse letlalo le hlakileng kapa le batlang le hlakile (IGA) libeke tsa 16 ha li bapisoa le karolo ea 22 lekholong ea bakuli ba nkang placebo hammoho le TCS. Libekeng tse 16, karolo ea 70 lekholong ea bakuli ba nkang lebrikizumab hammoho le TCS ba fihletse karabo ea EASI-75 ha e bapisoa le liperesente tse 42 tse nkang placebo hammoho le TCS. Phapang pakeng tsa bakuli ba fumanang lebrikizumab hammoho le TCS le placebo e nang le TCS e ile ea bonoa pele ho libeke tse 'nè bakeng sa EASI-75.

Bakuli ba tšoaroang ka lebrikizumab hammoho le TCS le bona ba finyelletse lintlafatso tsa bohlokoa ka lipalo-palo ho pholletsa le lintlha tsa bohlokoa tsa bobeli tse kenyeletsang ho tlosoa ha letlalo le ho hlohlona, ​​ho kena-kenana le ho hlohlona ha boroko, le mekhoa ea bophelo, ha e bapisoa le placebo e nang le TCS. Ho ile ha hlokomeloa liphapang tse nang le moelelo oa bongaka pele ho libeke tse 'nè bakeng sa ho hlohlona, ​​ho kena-kenana le ho hlohlona ha boroko, le litekanyetso tsa bophelo.

Liphetho tsa polokeho li ne li lumellana le lithuto tsa pele tsa lebrikizumab ho AD. Bakuli ba nkang lebrikizumab hammoho le TCS, ha ba bapisoa le placebo hammoho le TCS, ba tlalehile maqhubu a phahameng a liketsahalo tse mpe (lebrikizumab hammoho le TCS: 43%, placebo hammoho le TCS: 35%). Liketsahalo tse mpe tse ngata li ne li le bobebe kapa li itekanetse ka matla le tse se nang letho 'me li ne li sa lebise ho khaotsoe ke kalafo. Liketsahalo tse mpe tse atileng haholo ho ba lebrikizumab e ne e le conjunctivitis (5%) le hlooho (5%).

"Lilly o sebeletsa ho matlafatsa batho ba nang le mafu a amanang le letlalo, a kang atopic dermatitis, ho phela bophelo ba bona ka hohle kamoo ho ka khonehang," ho boletse Lotus Mallbris, MD, Ph.D., motlatsi oa mopresidente oa tsoelo-pele ea immunology le litaba tsa bongaka Lilly. . "Re hlokomela tlhoko ea bohlokoa ea likhetho tse ngata bakeng sa batho bao lefu la bona le ke keng la laoloa ka lihlooho. Re labalabela ho bona liphetho tse felletseng ho tsoa lenaneong la rona le pharalletseng la Mokhahlelo oa 3 le nts'etsopele ea lebrikizumab lefatšeng ka bophara.

Lilly o sa tsoa phatlalatsa lintlha tsa libeke tsa 16 tse tsoang lithutong tse tsoelang pele tsa ADvocate, 'me tlhahiso e kholo ea liphetho e hlahisitsoe ho RAD 2022. Ho phaella moo, lintlha tsa nako e telele tse tsoang lithutong tsa Advocate li tla senoloa likhoeling tse tlang.

"Liphetho tsena ke mohato o mong hape boitlamo ba rona ba ho fana ka liphekolo tse ncha tse etsang phapang e kholo ho bakuli. Re lebelletse ho phatlalatsa liketsahalo tsa bohlokoa tse ncha tse thabisang likhoeling tse tlang,” ho hlalosa Karl Ziegelbauer, Ph.D., Ofisiri e ka Sehloohong ea Saense ea Almirall SA.

Lilly o na le litokelo tse khethehileng bakeng sa nts'etsopele le khoebo ea lebrikizumab United States le lefats'eng lohle ka ntle ho Europe. Almirall e fane ka tumello ea ho hlahisa le ho rekisa lebrikizumab bakeng sa kalafo ea matšoao a letlalo, ho kenyeletsoa AD, Europe.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...